Inventor · disambiguated record
Taichi Kuramochi
Also filed as: KURAMOCHI TAICHI
31 granted patents·22 pending applications·560 citations·filing 2008–2024
97Inventor score
Top patents by PatentIndex Score
53 records- 0198US12122840B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Granted Oct 22, 2024·5 cites·24 claims
- 0298US12116414B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Granted Oct 15, 2024·5 cites·21 claims
- 0398US10253091B2Antibody constant region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Apr 9, 2019·27 cites·35 claims
- 0498US9828429B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Nov 28, 2017·40 cites·80 claims
- 0598US9096651B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRIGAWA TOMOYUKI·Filed 2008·Granted Aug 4, 2015·90 cites·44 claims
- 0697US11248053B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Feb 15, 2022·16 cites·28 claims
- 0796US11718678B2Method for altering plasma retention and immunogenicity of antigen-binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Aug 8, 2023·7 cites·16 claims
- 0896US11454633B2Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Sep 27, 2022·4 cites·19 claims
- 0996US10738111B2Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Aug 11, 2020·17 cites·25 claims
- 1096US10253100B2Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearanceCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Apr 9, 2019·37 cites·36 claims
- 1196US10000560B2Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Jun 19, 2018·26 cites·43 claims
- 1294US11142563B2Antigen-binding molecule containing modified Fc regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Oct 12, 2021·18 cites·53 claims
- 1394US10618965B2Method for altering plasma retention and immunogenicity of antigen-binding moleculeIGAWA TOMOYUKI·Filed 2012·Granted Apr 14, 2020·32 cites·33 claims
- 1494US8497355B2Anti-glypican-3 antibody having improved kinetics in plasmaIGAWA TOMOYUKI·Filed 2008·Granted Jul 30, 2013·29 cites·16 claims
- 1593US9890218B2Heterodimerized polypeptideMIMOTO FUTA·Filed 2012·Granted Feb 13, 2018·32 cites·39 claims
- 1693US8575317B2Anti-NR10 antibody and use thereofKURAMOCHI TAICHI·Filed 2009·Granted Nov 5, 2013·37 cites·14 claims
- 1792US10435458B2Antibody constant region variants with reduced Fcgammar bindingKURAMOCHI TAICHI·Filed 2011·Granted Oct 8, 2019·23 cites·2 claims
- 1891US11066483B2Cytotoxicity-inducing therapeutic agentNEZU JUNICHI·Filed 2011·Granted Jul 20, 2021·36 cites·48 claims
- 1991US9399680B2Nucleic acids encoding anti-NR10 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Jul 26, 2016·17 cites·37 claims
- 2091US2025011443A1Method of modifying isoelectric point of antibody via amino acid substitution in cdrCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 2189US9340615B2Anti-AXL antibodyMAEDA ATSUHIKO·Filed 2010·Granted May 17, 2016·23 cites·23 claims
- 2288US10150808B2Modified antibody constant regionsKURAMOCHI TAICHI·Filed 2010·Granted Dec 11, 2018·22 cites·5 claims
- 2388US2024294653A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 2487US11851476B2Antigen-binding molecule having regulated conjugation between heavy-chain and light-chainCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Dec 26, 2023·5 cites·27 claims
- 2587US2025076311A1Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 2686US11359009B2Anti-myostatin antibodies and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Granted Jun 14, 2022·5 cites·21 claims
- 2783US12479929B2Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Granted Nov 25, 2025·0 cites·21 claims
- 2882US2023183363A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2980US2024117059A1THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCECHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3080US2022389105A1Method of modifying isoelectric point of antibody via amino acid substitution in cdrCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3179US12371511B2Heterodimerized polypeptideCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Jul 29, 2025·1 cites·29 claims
- 3279US9556264B2Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredientCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Jan 31, 2017·5 cites·25 claims
- 3378US2023174655A1Fc-gamma-RIIb-SPECIFIC Fc ANTIBODYCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3475US2022064264A1Antibody constant region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3573US12077577B2Polypeptide comprising aggrecan binding domain and carrying moietyCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Sep 3, 2024·1 cites·27 claims
- 3671US2022041756A1Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3770US12252532B2Anti-myostatin antibodies and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Granted Mar 18, 2025·0 cites·6 claims
- 3868US2020002429A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 3967US12169205B2Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Dec 17, 2024·0 cites·5 claims
- 4067US2019211081A1Antibody constant region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 4166US2011129459A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2008·Application pending·0 cites
- 4263US2015175704A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Application pending·0 cites
- 4361US12084513B2Anti-C1S antibodies and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Sep 10, 2024·0 cites·18 claims
- 4461US2023257470A1Method for altering plasma retention and immunogenicity of antigen-binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 4560US12269876B2Modified Fc region of antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Apr 8, 2025·0 cites·13 claims
- 4659US2020087380A1Antigen-binding molecule having regulated conjugation between heavy-chain and light-chainCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 4758US2019233525A1THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCECHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 4856US2014093496A1Fc-gamma-RIIb-SPECIFIC Fc ANTIBODYMIMOTO FUTA·Filed 2012·Application pending·0 cites
- 4956US2013295612A1Anti-glypican-3 antibody having improved kinetics in plasmaCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Application pending·0 cites
- 5055US2012071634A1Antibody Constant Region VariantIGAWA TOMOYUKI·Filed 2010·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Taichi Kuramochi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →